New Delhi, May 19 -- Piramal Pharma Ltd has more than tripled investor wealth since 2023-24. With the Mumbai-based drug development and manufacturing company turning around its business recently, its stock has significantly outperformed the Nifty Pharma index the past two years. So why has the stock eroded 30% of investor wealth since its peak in November?

Already weighed down by global policy uncertainty, the Piramal Pharma counter has extended its correction after its earnings for the fourth quarter of 2024-25 disappointed investors.

But is the correction an opportunity for investors to buy the stock, or a signal of more stress to come?







Piramal Pharma is one of India's leading pharmaceutical companies with 17 manufacturing and ...